Impact of homogeneous pathologic response to preoperative chemotherapy in patients with multiple colorectal liver metastases

Table 2 Characteristics of the study population n (%)

Variable	Study population
Demographic data
Male gender	45 (61)
Age, median (range), yr	62.5 (40-80)
body mass index, mean ± SD, kg/m2	25.36 ± 4.42
Tumor markers
CEA level, mean ± SD (mg/L)	17 ± 3.5
Ca 19.9 level, mean ± SD (UI/L)	23 ± 5.2
Primary tumor site
Ascending colon	10 (14)
Transverse colon	5 (7)
Descending colon	33 (45)
Rectum	25 (34)
Liver metastases
Median (range) number of preoperative LM	3 (1-14)
Synchronous LM	55 (75)
Surgical procedure
Right hepatectomy	15 (16)
Left lobectomy	4 (4)
Right lobectomy	3 (3)
Posterior segmentectomy	8 (11)
Wedge	58 (66)
Two-stage hepatectomy	15 (17)
Site of the 300 metastases (%)
I	2.5
II	10
III	17.5
IV	11
V	16
VI	20
VII	13
VIII	10
Preoperative chemotherapy
Regimen
Folfox	28 (32)
Folfiri/Folfox and bevacizumab	28 (32)
Folfiri with or without cetuximab	8 (9)
Campto or folfiri with or without cetuximab	20 (23)
Folfirinox	4 (4)
Median (range) number of preoperative cycles	12 (4-38)
Pathology
T stage
2	7 (9)
3	56 (77)
4	10 (14)
N stage
0	18 (24)
1	37 (51)
2	11 (15)
X	7 (10)
Median (range) size of metastases, cm	3.1 (0.2-5)
PRPC
Rubbia-Brandt classification
Major response	13 (15)
Partial response	12 (14)
Absence of response	63 (71)
MD Anderson classification
Complete response	8 (9)
Major response	26 (30)
Minor response	54 (61)